



Press Release

PAT up by 19%
(1st Quarter FY 2024 Consolidated Results)

Mumbai, 27th July, 2023: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company today reported its performance for the 1st quarter ended 30th June 2023.

On July 9th, we celebrated a significant milestone - the 50th Anniversary of Ajanta Pharma. Today, our company stands strong and distinguished within the pharmaceutical industry. We have not only stood shoulder to shoulder with the leading companies, but we have also carved out our own unique mark of excellence.

Over the years, we have built large brands across geographies, state-of-the-art research and development centre, top-notch manufacturing facilities, robust quality systems and efficient business processes that are second to none. These accomplishments, significant as they are, aren't the only reasons for our success.

At the heart of Ajanta Pharma is its people. We've cultivated exceptional leadership, developed phenomenal teams, and nurtured a resilient culture of excellence.

On this occasion, we would like to thank all our stake holders: Ajantaites (existing and past), customers, suppliers, banks, business partners, associates, and shareholders for their support and contribution leading to Ajanta's success.

Interim Dividend:

Board of Directors have approved 1st interim dividend of Rs. 315 cr. for the year FY 2024. It translated into Rs. 25 per share (1250%) for each Rs. 2 face value share.

This total dividend of Rs. 25 per share includes a regular dividend of Rs. 10 per share, and an additional Rs. 15 per share, distributed as a special dividend on the commemoration of 50 years of momentous journey of the Company.

Q1 FY 2024 performance highlights (compared to Q1 FY 2023):

- Revenue from operations at Rs. 1,021 cr. against Rs. 951 cr.; up 7%.
- EBITDA at Rs. 271 cr. against Rs. 222 cr.; up 22%; EBITDA at 26%.
- Profit after tax at Rs. 208 cr. against Rs. 175 cr.; up 19%; PAT at 20%.

Branded Generic Business (Q1 FY 2024):

India	<p>Sale was Rs. 319 cr. (Rs. 279 cr.), up 14%.</p> <p>As per secondary market data of <u>IQVIA MAT June 2023</u>, Ajanta's growth was 15% versus IPM growth of 11%. Therapeutic growths are as below:</p> <ul style="list-style-type: none"> • <u>Cardiology</u>: 13% against segment growth of 11%. • <u>Ophthalmology</u>: 15% against segment growth of 12%. • <u>Dermatology</u>: 21% against segment growth of 8%. • <u>Pain Management</u>: 22% against segment growth of 12%.
--------------	--





Asia	Sale was Rs. 254 cr. (Rs. 240 cr.) up 6%.
Africa	Sale was Rs. 159 cr. (Rs. 168 cr.) down 5%.
Total Branded Generic	Sale was Rs. 732 cr. (Rs. 688 cr.) up 6%.

US Generic Business (Q1 FY 2024):

USA	<p>Sale was Rs. 213 cr. (Rs. 179 cr.) up 19%.</p> <p>During Q1:</p> <ul style="list-style-type: none"> • We received 3 ANDA final approval. • Filed 3 ANDA's. <p>Out of 49 final ANDA approvals, we have commercialized 41 products.</p> <p>We hold 3 tentative approvals and 21 ANDAs are awaiting US FDA approval.</p>
------------	--

Africa Institution Business (Q1 FY 2024):

Africa Institution	Sale was Rs. 65 cr. (Rs. 77 cr.) down 16%.
---------------------------	--

R&D (Q1 FY 2024):

R&D expenses were Rs. 55 cr., (Rs. 54 cr.), 5% of revenue.

Note: Figures in bracket are for corresponding year same period.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. This business contributes 73% in total revenue.

Company's state of the art R&D centre is located in Mumbai. Company has 7 world class manufacturing facilities located in India.

For last 5 financial years, company has posted healthy performance with its Revenue from Operations growing at 16% CAGR and net profit at 11% CAGR.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1600 hrs. IST (1830 hrs. SST/HKT, 1130 hrs. BST, 0630 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.





Dial-in Information

Date and Time	July 27, 2023 at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1130 – 1230 hrs BST 0630 – 0730 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
Diamond pass link	Click here to register
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement



Statement of Consolidated Unaudited Financial Results for the quarter ended 30 June 2023

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
	Unaudited	Audited (Refer Note 5)	Unaudited	Audited
Income				
Revenue from operations	1,021.04	881.84	950.93	3,742.64
Other income (Refer note 4)	31.75	36.83	32.76	98.64
Total Income	1,052.79	918.67	983.69	3,841.28
Expenses				
Cost of materials consumed	217.81	231.90	195.05	878.36
Purchases of stock-in-trade	39.64	29.27	36.54	146.28
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5.55)	(20.27)	48.83	25.76
Employee benefits expense	213.21	223.64	182.94	785.14
Finance costs	0.85	1.13	0.88	5.84
Depreciation and amortisation expense	33.18	33.02	31.78	130.80
Other expenses (Refer note 4)	284.61	267.93	265.81	1,123.85
Total Expenses	783.75	766.62	761.83	3,096.03
Profit before and after exceptional items but before tax	269.04	152.05	221.86	745.25
Tax Expense				
Current Tax (net)	68.32	56.99	45.51	197.24
Deferred Tax (net)	(7.40)	(27.19)	1.73	(39.97)
Profit after tax	208.12	122.25	174.62	587.98
Other Comprehensive Income (OCI)				
Items that will be reclassified subsequently to profit or loss	(2.02)	(3.41)	5.20	17.12
Income tax relating to Items that will be reclassified subsequently to profit or loss	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.96)	(2.14)	0.15	(3.49)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.75	(0.05)	1.22
Other Comprehensive Income for the year, net of tax	(2.64)	(4.80)	5.30	14.85
Total Comprehensive Income for the period	205.48	117.45	179.92	602.83
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.27	25.27	25.71	25.27
Other Equity				3,362.72
Earnings Per Share (Face value of ₹ 2 each)				
(a) Basic - in ₹	16.53	9.54	13.63	45.89
(b) Diluted - in ₹	16.53	9.54	13.63	45.89

Notes :

- The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 27 July 2023. The statutory auditors have expressed an unmodified opinion. The review report has been filed with the stock exchange and is available on company website.
- The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.
- Board of Directors have approved 1st interim dividend of ₹ 315 Crore for the financial year 2023-24 to its shareholders @ ₹ 25 per share (1250%) on the face value of ₹ 2 per share. This total dividend includes regular dividend of ₹ 10 per share (500%) and an additional ₹ 15 per share (750%) distributed as a special dividend on the commemoration of 50 years of momentous journey of the Company.
- Other income / Other expense includes :

₹ in Crore	3 months ended			Year Ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
Foreign exchange gain (in other income)	19.68	24.52	27.61	66.07
Foreign exchange loss (in other expense)	9.99	21.71	2.45	18.82

- The figures for the quarter ended 31 March 2023 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2022.
- During the quarter 1,000 (previous year 1,000) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to Share Based Incentive Plan, 2019, resulting in an increase in paid-up share capital by ₹ 2,000 (previous year ₹ 2,000) and securities premium by ₹ 0.18 crores (previous year ₹ 0.18 crores).
- On 10 March 2023, Company has announced buy back of its 22,10,500 equity shares, being 2.59% of the total paid up equity share capital at ₹ 1,425 per equity share for an aggregate amount of ₹ 315.00 crores. The buy back opened on 31 March 2023, closed on 10 April 2023 and Company extinguished those shares on 19 April 2023.
- The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

**SREEJA
 RAJASEKHA
 RAN MARAR**
 Digitally signed by
 SREEJA RAJASEKHARAN
 MARAR
 Date: 2023.07.27
 15:15:17 +05'30'

By order of the Board
 For Ajanta Pharma Ltd.

YOGESH MANNALA
 Digitally signed by
 YOGESH MANNALA
 AGRAWAL
 L
 Date: 2023.07.27
 14:28:48 +05'30'

Yogesh M. Agrawal
 Managing Director

Mumbai, 27 July 2023



Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2023

₹ in Crore

Particulars	3 months ended			Year Ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
	Unaudited	Audited (Refer Note 4)	Unaudited	Audited
Income				
Revenue from operations	1,014.58	848.86	850.29	3,411.27
Other income (Refer note 3)	31.46	36.75	35.42	132.75
Total Income	1,046.04	885.61	885.71	3,544.02
Expenses				
Cost of materials consumed	217.81	231.89	195.05	878.36
Purchases of stock-in-trade	39.46	39.22	33.43	149.04
Changes in inventories of finished goods, work-in-progress and stock-in-trade	34.40	(6.03)	32.09	(21.99)
Employee benefits expense	196.30	207.06	166.92	720.41
Finance costs	0.75	1.21	0.63	5.23
Depreciation and amortisation expense	32.24	32.11	30.75	126.95
Other expenses (Refer note 3)	249.71	232.19	236.49	986.17
Total Expenses	770.67	737.65	695.36	2,844.17
Profit before and after exceptional items but before tax	275.37	147.96	190.35	699.85
Tax Expense				
Current Tax (net)	60.58	39.20	41.81	144.06
Deferred Tax (net)	2.75	(8.45)	(1.83)	(2.93)
Profit after tax	212.04	117.21	150.37	558.72
Other Comprehensive Income (OCI)				
Items that will not be reclassified subsequently to profit or loss	(0.96)	(2.14)	0.15	(3.49)
Income tax relating to items that will not be reclassified to profit or loss	0.34	0.75	(0.05)	1.22
Other Comprehensive Income for the year, net of tax	(0.62)	(1.39)	0.10	(2.27)
Total Comprehensive Income for the period	211.42	115.82	150.47	556.45
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.27	25.27	25.71	25.27
Other Equity				3,221.18
Earnings Per Share (Face value of ₹ 2 each)				
(a) Basic - in ₹	16.84	9.15	11.74	43.61
(b) Diluted - in ₹	16.84	9.15	11.74	43.61

Notes :

- The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 27 July 2023. The statutory auditors have expressed an unmodified opinion. The review report has been filed with the stock exchange and is available on company website.
- Board of Directors have approved 1st interim dividend of ₹ 315 Crore for the financial year 2023-24 to its shareholders @ ₹ 25 per share (1250%) on the face value of ₹ 2 per share. This total dividend includes regular dividend of ₹ 10 per share (500%) and an additional ₹ 15 per share (750%) distributed as a special dividend on the commemoration of 50 years of momentous journey of the Company.
- Other income / Other expense includes :

₹ in Crore	3 months ended			Year Ended
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
Dividend from subsidiaries (in other income)	-	-	-	35.14
Foreign exchange gain (in other income)	19.68	24.52	33.35	68.48
Foreign exchange loss (in other expense)	6.97	23.78	2.45	18.82

- The figures for the quarter ended 31 March 2023 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2022.
- During the quarter 1,000 (previous year 1,000) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by ₹ 2,000 (previous year ₹ 2,000) and securities premium by ₹ 0.18 crores (previous year ₹ 0.18 crores).
- On 10 March 2023, Company has announced buy back of its 22,10,500 equity shares, being 2.59% of the total paid up equity share capital at ₹ 1,425 per equity share for an aggregate amount of ₹ 315.00 crores. The buy back opened on 31 March 2023, closed on 10 April 2023 and Company extinguished those shares on 19 April 2023.
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- The Financial Results are available on the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com.

**SREEJA
RAJASEKHARA
N MARAR**

Digitally signed by
SREEJA RAJASEKHARAN
MARAR
Date: 2023.07.27 15:16:02
+05'30'

Mumbai, 27 July 2023

By order of the Board
For Ajanta Pharma Ltd.

YOGESH
MANNALA
L
AGRAWAL

Digitally signed
by YOGESH
MANNALA
AGRAWAL
Date: 2023.07.27
14:29:38 +05'30'

Yogesh M. Agrawal
Managing Director

